Global deployment OptraSCAN is already deployed in 30+ countries, indicating a scalable international footprint and potential for channel partners or regional expansion deals to accelerate adoption in new markets.

Pay-per-use expansion New HistoSiA Breast pay-per-use offering suggests a flexible pricing model that can lower adoption barriers for labs with limited budgets, presenting an upsell path for existing customers and a target for new mid-market labs.

TB and imaging focus Recent launches of BactoSiA for TB treatment monitoring and TB smear standardization highlight a strong opportunity to sell end-to-end AI-enabled imaging workflows to reference labs and public health programs focusing on TB.

Breast and HER2 pilots HER2 pilot programs and breast cancer analytics capabilities position OptraSCAN to engage cancer centers and pathology departments seeking digital/AI-assisted biomarker workflows and remote collaboration.

Integrated platform End-to-end solution blending scanners, AI analytics, image management, and telepathology enables cross-sell of modules (imaging, analysis, IMS, TELEPath) to labs looking to modernize across multiple pathology use cases.